Mizuho analyst Salim Syed raised the firm’s price target on Gilead Sciences to $101 from $88 and keeps a Buy rating on the shares. In a post-Q4 model update, the analyst increased the firm’s peak sales estimates for Gilead’s HIV business to $20B from $19B.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD: